ArticleFrontiers in bioinformatics2025
TRANSAID: a hybrid deep learning framework for translation site prediction with integrated biological feature scoring.
Article in Frontiers in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MetaTIS: a tool to predict cognate and near-cognate translation initiation sites in human.NAR genomics and bioinformatics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Translation initiation and termination are critical regulatory checkpoints in protein synthesis, yet accurate computational prediction of their sites remains challenging due to training data biases and the complexity of full-length transcripts. Methods: To address these limitations, we present TRANSAID (TRANSlation AI for Detection), a novel deep learning framework that accurately and simultaneously predicts translation initiation (TIS) and termination (TTS) sites from complete transcript sequences. TRANSAID's hierarchical architecture efficiently processes long transcripts, capturing both local motifs and long-range dependencies. Crucially, the model was trained on a human transcriptome dataset that was rigorously partitioned at the gene level to prevent data leakage and included both protein-coding (NM) and non-coding (NR) transcripts. Results: This mixed-training strategy enables TRANSAID to achieve high fidelity, correctly identifying 73.61% of NR transcripts as non-coding. Performance is further enhanced by an integrated biological scoring system, improving "perfect ORF prediction" for coding sequences to 94.94% and "correct non-coding prediction" to 82.00%. The human-trained model demonstrates remarkable cross-species applicability, maintaining high accuracy on organisms from mammals to yeast. Beyond annotation, TRANSAID serves as a powerful discovery tool for novel coding events. When applied to long-read sequencing data, it accurately identified previously unannotated protein isoforms validated by mass spectrometry (76.28% validation rate). Furthermore, homology searches of high-scoring ORFs predicted within NR transcripts suggest a strong potential for identifying cryptic translation events. Discussion: As a fully documented open-source tool with a user-friendly web server, TRANSAID provides a powerful and accessible resource for improving transcriptome annotation and proteomic discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.